Conference Coverage

SGLT inhibition back on track in phase 3 type T1DM trial

Publish date: October 18, 2017

 

AT EASD 2017

Pages

Recommended Reading

Many years on metformin linked to anemia risk
MDedge Internal Medicine
Fasting glucose fluctuations, severe hypoglycemia up T2DM death risk
MDedge Internal Medicine
Semaglutide aids T2DM weight loss over 2 years
MDedge Internal Medicine
Insulin pumps associated with lower risk of ketoacidosis and severe hypoglycemia in kids
MDedge Internal Medicine
Intensified approach reduces long-term heart failure risk in T2DM
MDedge Internal Medicine
Triple therapy for type 2 diabetes goes beyond glucose control
MDedge Internal Medicine
Nearly 10% of patients with candidemia had CDI
MDedge Internal Medicine
Exercise reduces T1DM mortality risk
MDedge Internal Medicine
Oral semaglutide achieves outcomes similar to those of subcutaneous semaglutide
MDedge Internal Medicine
Vitality predicts T2DM major cardiovascular event risk
MDedge Internal Medicine